Global and United States Antidiabetic Glucagon-like Peptide 1 Agonists Market Report & Forecast 2022-2028

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Market Analysis and Insights: Global and United States Antidiabetic Glucagon-like Peptide 1 Agonists Market

This report focuses on global and United States Antidiabetic Glucagon-like Peptide 1 Agonists market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Exenatied accounting for % of the Antidiabetic Glucagon-like Peptide 1 Agonists global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the Antidiabetic Glucagon-like Peptide 1 Agonists market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Antidiabetic Glucagon-like Peptide 1 Agonists Scope and Market Size

Antidiabetic Glucagon-like Peptide 1 Agonists market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Antidiabetic Glucagon-like Peptide 1 Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Antidiabetic Glucagon-like Peptide 1 Agonists market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Antidiabetic Glucagon-like Peptide 1 Agonists market is segmented into

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Segment by Application, the Antidiabetic Glucagon-like Peptide 1 Agonists market is segmented into

Hospital

Pharmacy

Regional and Country-level Analysis

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Landscape and Antidiabetic Glucagon-like Peptide 1 Agonists Market Share Analysis

Antidiabetic Glucagon-like Peptide 1 Agonists market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Antidiabetic Glucagon-like Peptide 1 Agonists business, the date to enter into the Antidiabetic Glucagon-like Peptide 1 Agonists market, Antidiabetic Glucagon-like Peptide 1 Agonists product introduction, recent developments, etc.

The major vendors covered:

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb